By medication, the asthma drugs market is bifurcated into quick relief medication, long term control medications. The long term control medications segment dominated the market in 2025. Long-term control medications lead the market as they are essential for managing chronic inflammation in asthma patients. Unlike quick-relief drugs, which address immediate symptoms, long-term therapies such as inhaled corticosteroids and leukotriene modifiers prevent frequent exacerbations and improve quality of life. The growing emphasis on proactive asthma management, adherence to treatment guidelines, and rising awareness among healthcare providers and patients about preventing severe attacks contribute to their dominant position in the market.
By drug class, the market is categorized into bronchodilators, corticosteroids, leukotriene modifiers, combination medications, other drug class. The corticosteroids segment held the largest share of the market in 2025. Corticosteroids are the leading drug class due to their potent anti-inflammatory properties, which effectively reduce airway inflammation, a root cause of asthma symptoms. Inhaled corticosteroids, in particular, are widely prescribed as first-line therapy for persistent asthma, ensuring better disease control with minimal systemic side effects. Their efficacy in preventing exacerbations, combined with widespread clinical adoption and guideline recommendations, has solidified corticosteroids as the most preferred treatment option among both physicians and patients globally.
By mode of administration, the market is segmented into inhaler, prefilled syringe/vials, tablet and capsules, liquid preparation. The inhaler segment held the largest share of the market in 2025. Inhalers dominate the mode of administration segment because they deliver medication directly to the lungs, ensuring rapid onset of action and improved therapeutic efficiency. They are portable, convenient, and minimize systemic side effects compared to oral or injectable forms. Patient preference for ease of use, combined with increasing adoption of metered-dose and dry powder inhalers, supports this trend. Additionally, healthcare guidelines recommend inhalation therapy as the primary route for both quick-relief and long-term asthma management, reinforcing their leading position.
By age group, the market is bifurcated into pediatric, adults. The adults segment held a larger share of the market in 2025. The adult segment leads due to a higher prevalence of diagnosed asthma cases in this population, coupled with greater awareness and access to healthcare services. Adults are more likely to seek treatment, adhere to prescribed therapies, and manage chronic conditions proactively. Lifestyle factors such as exposure to pollution, smoking, and occupational triggers also contribute to increased asthma incidence in adults, driving demand for both maintenance and rescue medications. Pediatric asthma management, while significant, remains comparatively smaller due to age-specific dosing limitations and parental monitoring.
By distribution channel, the asthma drugs market is segmented into hospital pharmacies, retail pharmacies, online pharmacies. The retail pharmacies segment dominated the market in 2025. Retail pharmacies are the leading distribution channel because they provide easy accessibility, wide geographic coverage, and convenience for patients. They cater to both prescription and over-the-counter asthma medications, allowing timely access for maintenance therapy and emergency relief drugs. Strong relationships between pharmaceutical companies and retail chains, coupled with increasing urbanization and consumer preference for local pharmacy purchases, further boost their dominance. Retail pharmacies also offer personalized guidance and counseling, enhancing patient adherence and trust in asthma treatment.
